Gaosheng Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gaosheng Huang has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Wei Zhang
Department of Pathology, Tangdu Hospital, Fourth Military Medical University, Xi’an, China
5 shared publications Jing Tian
Department of Pathology, Helmholtz Sina-German Research Laboratory for Cancer, Tangdu Hospital, Air Force Medical University, Xi’an, People’s Republic of China
4 shared publicationsLi Gong
Department of Pathology, Helmholtz Sina-German Research Laboratory for Cancer, Tangdu Hospital, Air Force Medical University, Xi’an, People’s Republic of China
4 shared publicationsFuqin Zhang
Department of Pathology, Helmholtz Sina-German Research Laboratory for Cancer, Tangdu Hospital, Air Force Medical University, Xi’an, People’s Republic of China
3 shared publicationsQiannan Wang
Department of Pathology, Helmholtz Sina-German Research Laboratory for Cancer, Tangdu Hospital, Air Force Medical University, Xi’an, People’s Republic of China
3 shared publicationsYan Wang
Department of Stomatology, Tangdu Hospital, Air Force Medical University, Xi’an, People’s Republic of China
3 shared publications
Latest Publications
- 4 January 2023
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30  (3) , 1658-1659
ASO Visual Abstract: Human Parvovirus B19 May Be a Risk Factor in Myasthenia Gravis with Thymoma
- 4 January 2023
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30  (3) , 1658-1659
ASO Visual Abstract: Human Parvovirus B19 May Be a Risk Factor in Myasthenia Gravis with Thymoma
- Open Access
- 22 December 2022
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30  (3) , 1662
Correction: Human Parvovirus B19 May Be a Risk Factor in Myasthenia Gravis with Thymoma
- 22 December 2022
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30  (3) , 1662
Open AccessCorrection: Human Parvovirus B19 May Be a Risk Factor in Myasthenia Gravis with Thymoma
- 21 December 2022
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30  (3) , 1656-1657
ASO Author Reflections: A Possible New Etiology of Thymoma-Associated Myasthenia Gravis—Human Parvovirus B19
- 21 December 2022
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30  (3) , 1656-1657
ASO Author Reflections: A Possible New Etiology of Thymoma-Associated Myasthenia Gravis—Human Parvovirus B19
- 12 December 2022
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30  (3) , 1646-1655
Human Parvovirus B19 May Be a Risk Factor in Myasthenia Gravis with Thymoma
Our previous studies have demonstrated that human parvovirus B19 (B19V) is involved in the pathogenesis of thymic hyperplasia-associated myasthenia gravis
- 12 December 2022
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30  (3) , 1646-1655
Human Parvovirus B19 May Be a Risk Factor in Myasthenia Gravis with Thymoma
Our previous studies have demonstrated that human parvovirus B19 (B19V) is involved in the pathogenesis of thymic hyperplasia-associated myasthenia gravis
- 1 January 2019
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 25  (1) , 109.e7-109.e12
Detection of human parvovirus B19 infection in the thymus of patients with thymic hyperplasia-associated myasthenia gravis
- 1 January 2019
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 25  (1) , 109.e7-109.e12
Detection of human parvovirus B19 infection in the thymus of patients with thymic hyperplasia-associated myasthenia gravis
- Open Access
- 8 June 2016
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 14  (1) , 1-13
MicroRNA-142-5p contributes to Hashimoto’s thyroiditis by targeting CLDN1
MicroRNAs have the potential as diagnostic biomarkers and therapeutic targets in autoimmune diseases. However, very limited studies have evaluated the expression of microRNA profile in thyroid gland related to Hashimoto’s thyroiditis (HT). MicroRNA microarray expression profiling was performed and validated by quantitative RT-PCR. The expression pattern of miR-142-5p was detected using locked nucleic acid-in situ hybridization. The target gene was predicted and validated using miRNA targets prediction database, gene expression analysis, quantitative RT-PCR, western blot, and luciferase assay. The potential mechanisms of miR-142-5p were studied using immunohistochemistry, immunofluorescence, and quantitative assay of thyrocyte permeability. Thirty-nine microRNAs were differentially expressed in HT (Fold change ≥2, P < 0.05) and miR-142-5p, miR-142-3p, and miR-146a were only high expression in HT thyroid gland (P < 0.001). miR-142-5p, which was expressed at high levels in injured follicular epithelial cells, was also detected in HT patient serum and positively correlated with thyroglobulin antibody (r ≥ 0.6, P < 0.05). Furthermore, luciferase assay demonstrated CLDN1 was the direct target gene of miR-142-5p (P < 0.05), and Immunohistochemical staining showed a reverse expression patterns with miR-142-5p and CLDN1. Overexpression of miR-142-5p in thyrocytes resulted in reducing of the expression of claudin-1 both in mRNA and protein level (P = 0.032 and P = 0.009 respectively) and increasing the permeability of thyrocytes monolayer (P < 0.01). Our findings indicate a previously unrecognized mechanism that miR-142-5p, targeting CLDN1, plays an important role in HT pathogenesis.
- 8 June 2016
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 14  (1) , 1-13
Open AccessMicroRNA-142-5p contributes to Hashimoto’s thyroiditis by targeting CLDN1
MicroRNAs have the potential as diagnostic biomarkers and therapeutic targets in autoimmune diseases. However, very limited studies have evaluated the expression of microRNA profile in thyroid gland related to Hashimoto’s thyroiditis (HT). MicroRNA microarray expression profiling was performed and validated by quantitative RT-PCR. The expression pattern of miR-142-5p was detected using locked nucleic acid-in situ hybridization. The target gene was predicted and validated using miRNA targets prediction database, gene expression analysis, quantitative RT-PCR, western blot, and luciferase assay. The potential mechanisms of miR-142-5p were studied using immunohistochemistry, immunofluorescence, and quantitative assay of thyrocyte permeability. Thirty-nine microRNAs were differentially expressed in HT (Fold change ≥2, P < 0.05) and miR-142-5p, miR-142-3p, and miR-146a were only high expression in HT thyroid gland (P < 0.001). miR-142-5p, which was expressed at high levels in injured follicular epithelial cells, was also detected in HT patient serum and positively correlated with thyroglobulin antibody (r ≥ 0.6, P < 0.05). Furthermore, luciferase assay demonstrated CLDN1 was the direct target gene of miR-142-5p (P < 0.05), and Immunohistochemical staining showed a reverse expression patterns with miR-142-5p and CLDN1. Overexpression of miR-142-5p in thyrocytes resulted in reducing of the expression of claudin-1 both in mRNA and protein level (P = 0.032 and P = 0.009 respectively) and increasing the permeability of thyrocytes monolayer (P < 0.01). Our findings indicate a previously unrecognized mechanism that miR-142-5p, targeting CLDN1, plays an important role in HT pathogenesis.
- 1 December 2015
- Published by Elsevier in Human Pathology
- Vol. 46  (12) , 1913-1921
PRDM1 expression via human parvovirus B19 infection plays a role in the pathogenesis of Hashimoto thyroiditis
- 1 December 2015
- Published by Elsevier in Human Pathology
- Vol. 46  (12) , 1913-1921
PRDM1 expression via human parvovirus B19 infection plays a role in the pathogenesis of Hashimoto thyroiditis